Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).

导出 LinkOut

翻译打印收藏纠错

作者： Yi,Fang ^[1] ; Jing-Xin,Li ^[2] ; Davone,Duangdany ^[3] ; Yang,Li ^[1] ; Xi-Lin,Guo ^[2] ; Chanthala,Phamisith ^[4] ; Bo,Yu ^[1] ; Ming-Yun,Shen ^[1] ; Bin,Luo ^[1] ; Yu-Zhu,Wang ^[1] ; Si-Jun,Liu ^[1] ; Fan-Fan,Zhao ^[1] ; Cong-Cong,Xu ^[1] ; Xu-Hui,Qiu ^[1] ; Rong,Yan ^[1] ; Yu-Zhou,Gui ^[5] ; Rong-Juan,Pei ^[6] ; Jie,Wang ^[7] ; Haifa,Shen ^[1] ; Wu-Xiang,Guan ^[1] ; Hang-Wen,Li ^[7] ; Mayfong,Mayxay ^[1]

作者单位： Stemirna Therapeutics, Shanghai, China. ^[1] Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. ^[2] Food and Drug Department, Ministry of Health, Vientiane, Laos. ^[3] Savannakhet Province Hospital, Savannakhet, Laos. ^[4] Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China. ^[5] Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China. ^[6] Wuhan Institute of Virology, Wuhan, China. ^[7] University of Health Sciences, Ministry of Health, Vientiane, Laos. ^[8]

关键词 COVID-19 Heterologous boosting Lipopolyplex (LPP)Phase 3 trial SARS-CoV-2 mRNA vaccine

DOI 10.1016/j.eclinm.2023.102372

PMID 38169790

发布时间 2024-01-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

EClinicalMedicine

2024年67卷

102372页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).

EClinicalMedicine

相似文献

EClinicalMedicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).

EClinicalMedicine

相似文献

EClinicalMedicine

相关期刊

检索历史清除